Published in Am J Trop Med Hyg on May 01, 1975
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites (SPZ-Irrad) | NCT01082341
Malaria: progress, perils, and prospects for eradication. J Clin Invest (2008) 6.54
Acquired immunity to malaria. Clin Microbiol Rev (2009) 6.24
Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med (1980) 4.81
Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med (2002) 2.38
Integrated approach to malaria control. Clin Microbiol Rev (2002) 2.15
Naturally-Acquired Immune Response against Plasmodium vivax Rhoptry-Associated Membrane Antigen. PLoS One (2016) 2.05
Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci U S A (1992) 2.00
Monoclonal antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Proc Natl Acad Sci U S A (1982) 1.82
Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci (2011) 1.70
Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog (2010) 1.64
Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe (2011) 1.61
CD8+ T effector memory cells protect against liver-stage malaria. J Immunol (2011) 1.55
Helminth infection impairs the immunogenicity of a Plasmodium falciparum DNA vaccine, but not irradiated sporozoites, in mice. Vaccine (2010) 1.54
Susceptibility of different strains of mice to hepatic infection with Plasmodium berghei. Infect Immun (1994) 1.49
DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One (2013) 1.47
Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog (2010) 1.39
Plasmodium berghei sporozoite invasion is blocked in vitro by sporozoite-immobilizing antibodies. Infect Immun (1986) 1.37
Cardiac complication after experimental human malaria infection: a case report. Malar J (2009) 1.35
Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine. J Exp Med (1987) 1.35
Evaluation of an in vitro assay aimed at measuring protective antibodies against sporozoites. Bull World Health Organ (1990) 1.30
Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun (2006) 1.30
T-cell immunity to peptide epitopes of liver-stage antigen 1 in an area of Papua New Guinea in which malaria is holoendemic. Infect Immun (1997) 1.27
Immunity to falciparum and vivax malaria induced by irradiated sporozoites: a review of the University of Maryland studies, 1971-75. Bull World Health Organ (1990) 1.26
A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun (2006) 1.25
Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS One (2011) 1.25
Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med (1995) 1.23
Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. Infect Immun (2003) 1.21
Development of immunity in natural Plasmodium falciparum malaria: antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32). J Clin Microbiol (1987) 1.18
A blood stage antigen of Plasmodium falciparum shares determinants with the sporozoite coat protein. Proc Natl Acad Sci U S A (1985) 1.17
Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One (2010) 1.14
Minimal role for the circumsporozoite protein in the induction of sterile immunity by vaccination with live rodent malaria sporozoites. Infect Immun (2010) 1.06
Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor. Malar J (2004) 1.01
Malaria vaccine development. Clin Microbiol Rev (1994) 1.01
Class II-restricted protective immunity induced by malaria sporozoites. Infect Immun (2007) 1.00
Analysis of immune responses against T- and B-cell epitopes from Plasmodium falciparum liver-stage antigen 1 in rodent malaria models and malaria-exposed human subjects in India. Infect Immun (2000) 0.96
Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine (2015) 0.95
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother (2012) 0.95
Transcriptional analysis of the pre-erythrocytic stages of the rodent malaria parasite, Plasmodium yoelii. PLoS One (2010) 0.95
Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements. Infect Dis Poverty (2014) 0.93
Inhibition of T cell function during malaria: implications for immunology and vaccinology. J Exp Med (2003) 0.93
Analysis of the human antibody response to thrombospondin-related anonymous protein of Plasmodium falciparum. Infect Immun (1993) 0.93
Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice. Vaccine (2011) 0.92
Superinfection in malaria: Plasmodium shows its iron will. EMBO Rep (2011) 0.91
Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc Natl Acad Sci U S A (2014) 0.91
Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine (2010) 0.90
A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther (2014) 0.89
Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect Immun (2007) 0.89
Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites. Bull World Health Organ (1990) 0.89
Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model. PLoS One (2010) 0.87
Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin. Infect Immun (2013) 0.85
Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. Infect Immun (2006) 0.85
T lymphocytes from mice immunized with irradiated sporozoites eliminate malaria from hepatocytes. Bull World Health Organ (1990) 0.85
Skin-draining lymph node priming is sufficient to induce sterile immunity against pre-erythrocytic malaria. EMBO Mol Med (2012) 0.85
Tailoring a Combination Preerythrocytic Malaria Vaccine. Infect Immun (2015) 0.84
Malaria vaccine research and development: the role of the WHO MALVAC committee. Malar J (2013) 0.83
CD8 T cell independent immunity after single dose infection-treatment-vaccination (ITV) against Plasmodium yoelii. Vaccine (2013) 0.83
Designing malaria vaccines to circumvent antigen variability. Vaccine (2015) 0.83
Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development. PLoS One (2015) 0.82
Correlates of protective immunity following whole sporozoite vaccination against malaria. Immunol Res (2014) 0.81
Measuring naturally acquired ex vivo IFN-γ responses to Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (CelTOS) in Ghanaian adults. Malar J (2015) 0.80
Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites. Am J Trop Med Hyg (2011) 0.80
Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection. Infect Immun (2015) 0.79
Vaccines against malaria. Clin Infect Dis (2014) 0.79
Experimental models in vaccine research: malaria and leishmaniasis. Braz J Med Biol Res (2013) 0.79
X-irradiation of Eimeria tenella oocysts provides direct evidence that sporozoite invasion and early schizont development induce a protective immune response(s). Infect Immun (1991) 0.79
A Sporozoite- and Liver Stage-expressed Tryptophan-rich Protein Plays an Auxiliary Role in Plasmodium Liver Stage Development and Is a Potential Vaccine Candidate. J Biol Chem (2015) 0.78
Identification of pre-erythrocytic malaria antigens that target hepatocytes for killing in vivo and contribute to protection elicited by whole-parasite vaccination. PLoS One (2014) 0.78
The role of cytokines in malaria infection. Bull World Health Organ (1990) 0.78
Boosting the Immune Response: The Use of iNKT cell ligands as vaccine adjuvants. Front Biol (Beijing) (2012) 0.78
An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses. PLoS One (2014) 0.77
Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial. PLoS Negl Trop Dis (2016) 0.76
CD8(+) T Cell Responses to Plasmodium and Intracellular Parasites. Curr Immunol Rev (2013) 0.76
Malaria vaccines and human immune responses. Curr Opin Microbiol (2016) 0.76
Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes. Wien Klin Wochenschr (2006) 0.76
Plasmodium vivax Controlled Human Malaria Infection - Progress and Prospects. Trends Parasitol (2016) 0.76
Measurement of the T Cell Response to Preerythrocytic Vaccination in Mice. Methods Mol Biol (2015) 0.76
Molecular cloning and sequencing of the circumsporozoite protein gene from Plasmodium falciparum strain FCC-1/HN and expression of the gene in Mycobacteria. J Clin Microbiol (2001) 0.75
Approaches to malaria vaccine development using the retrospectroscope. Infect Immun (2009) 0.75
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malar J (2016) 0.75
Why not vaccinate against malaria? Br Med J (Clin Res Ed) (1981) 0.75
Profiling the host response to malaria vaccination and malaria challenge. Vaccine (2015) 0.75
Prospects for the development of malaria vaccines. Bull World Health Organ (1981) 0.75
Discriminating Protective from Nonprotective Plasmodium-Specific CD8+ T Cell Responses. J Immunol (2016) 0.75
Development of a malaria vaccine. J R Soc Med (1978) 0.75
The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med (1976) 7.89
Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci (1973) 4.18
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature (1987) 3.51
A quinoline methanol (WR 30090) for treatment of acute malaria. Antimicrob Agents Chemother (1973) 2.85
Suppressive activity of mefloquine in sporozoite-induced human malaria. Antimicrob Agents Chemother (1976) 2.71
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
A phenanthrene methanol (WR 33063) for treatment of acute malaria. Antimicrob Agents Chemother (1973) 2.05
Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci (1973) 1.84
Treatment of falciparum malaria caused by strain resistant to quinine. JAMA (1970) 1.81
Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. Am J Trop Med Hyg (1977) 1.64
Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp Parasitol (1977) 1.59
Prophylactic activity of a phenanthrene methanol (WR 33063) and a quinoline methanol (WR 30090) in human malaria. Antimicrob Agents Chemother (1973) 1.57
Clinical problems associated with the use of primaquine as a tissue schizontocidal and gametocytocidal drug. Bull World Health Organ (1981) 1.47
Antimalarial effects of tetracyclines in man. J Trop Med Hyg (1971) 1.19
Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection. J Clin Microbiol (1989) 1.07
Prophylaxis of malaria in man using the sulfones DFD and DDS alone and with chloroquine. Mil Med (1971) 0.99
Drug resistance in the human malarias. Antibiot Chemother (1971) (1975) 0.94
Continuation of chloroquine-susceptible Plasmodium falciparum parasitemia in volunteers receiving chloroquine therapy. Antimicrob Agents Chemother (1990) 0.93
Estimate of Plasmodium falciparum sporozoite content of Anopheles stephensi used to challenge human volunteers. Am J Trop Med Hyg (1989) 0.91
Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites. Bull World Health Organ (1990) 0.89
Diformyl diaminodiphenyl sufone (DFD) as an antimalarial in man. Mil Med (1970) 0.87
Suppression of malaria in Tanzania with the use of medicated salt. Bull World Health Organ (1966) 0.87
A model for Plasmodium falciparum sporozoite challenge and very early therapy of parasitaemia for efficacy studies of sporozoite vaccines. Trop Geogr Med (1988) 0.86
Antimalarial effects of clindamycin in man. Am J Trop Med Hyg (1975) 0.85
Prophylaxis of malaria in man using the sulfone DFD with pyrimethamine. Mil Med (1973) 0.85
Plasmodium falciparum: in vitro characterization and human infectivity of a cloned line. Exp Parasitol (1992) 0.85
Drug resistance of malaria parasites in Tanzania. East Afr Med J (1966) 0.84
Resistance to chloroquine of Plasmodium falciparum from Burma. Trans R Soc Trop Med Hyg (1972) 0.84
Prophylactic and sporontocidal treatment of chloroquine resistant Plasmodium falciparum from Malaya. Trans R Soc Trop Med Hyg (1970) 0.83
Sulfalene and trimethoprim in acute falciparum malaria. JAMA (1969) 0.83
Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3. Trans R Soc Trop Med Hyg (1990) 0.83
Urinary neopterin in volunteers experimentally infected with Plasmodium falciparum. Trans R Soc Trop Med Hyg (1992) 0.83
Serum glycoproteins in experimentally induced malaria in man. J Lab Clin Med (1968) 0.82
Characterization of a drug resistant strain of Plasmodium falciparum from the Philippines. J Trop Med Hyg (1971) 0.82
Prophylactic and sporontocidal treatment of chloroquine-resistant Plasmodium falciparum from Vietnam. Am J Trop Med Hyg (1971) 0.80
Influence of sulfalene upon gametocytogenesis of Plasmodium falciparum and subsequent infection patterns in Anopheles stephensi. Exp Parasitol (1973) 0.80
Characteristics of Plasmodium falciparum from the Solomon Islands. J Trop Med Hyg (1974) 0.80
Antimalarial effect of diaphenylsulfone and three sulfonamides among semi-immune Africans. Am J Trop Med Hyg (1967) 0.80
Letter: Resistance to chloroquine of Plasmodium falciparum from Sabah. Trans R Soc Trop Med Hyg (1973) 0.79
Characterization of a drug resistant strain of Plasmodium falciparum from Burma. J Trop Med Hyg (1973) 0.79
Field trials of repository antimalarial compounds. J Trop Med Hyg (1969) 0.79
Characterisation of a drug resistant strain of Plasmodium falciparum from Sabah. J Trop Med Hyg (1973) 0.78
Malaria eradication in East Africa. East Afr Med J (1965) 0.78
Treatment of drug-resistant malaria in man. Bull World Health Organ (1974) 0.77
Chloroquine-resistant falciparum malaria from Irian Jaya (Indonesian New Guinea). J Trop Med Hyg (1976) 0.77
Effects of ingested human anti-sporozoite sera on Plasmodium falciparum sporogony in Anopheles stephensi. Am J Trop Med Hyg (1993) 0.77
A modified leukocyte nitroblue tetrazolium test in acute bacterial infection. Am J Clin Pathol (1976) 0.77
The problem of drug-resistant malaria. Am J Trop Med Hyg (1972) 0.76
Characteristics of four new drug-resistant strains of Plasmodium falciparum from South-East Asia. Mil Med (1969) 0.76
Comparative efficiency of Anopheles stephensi and Anopheles gambiae as vectors of drug-resistant Plasmodium falciparum from Thailand. Am J Trop Med Hyg (1974) 0.76
Treatment of multi-drug resistant malaria. East Afr Med J (1967) 0.75
Malaria in Maryland since 1960: incidence and research. Md Med J (1989) 0.75
Malaria distribution in Tanganyika. VI. Western Tanzania. East Afr Med J (1965) 0.75
Responsibility for failure of sulphonamides in falciparum malaria; host or parasite? Trans R Soc Trop Med Hyg (1972) 0.75
Treatment of falciparum malaria with sulfalene and trimethoprim. Am J Trop Med Hyg (1971) 0.75
Malaria distribution in Tanganyika. V. The north. East Afr Med J (1965) 0.75
Plasmodium falciparum: responses of a semi-immune individual to homologous and heterologous challenges, and non-infectivity of gametocytes in Anopheles stephensi. Am J Trop Med Hyg (1978) 0.75
Acetylator phenotype in sulphonamide resistant falciparum malaria. Ann Trop Med Parasitol (1974) 0.75
Characterization and pathophysiology of serum glycoprotein alterations in malaria. J Lab Clin Med (1972) 0.75